Android app on Google Play

Janssen Approved for Expanded Indication of ZYTIGA (JNJ)

December 10, 2012 1:41 PM EST Send to a Friend
Johnson & Johnson's (NYSE: JNJ) Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate). Until now, ZYTIGA with prednisone has only been approved to treat men with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. With this approval, ZYTIGA, in combination with prednisone, may now be used earlier in the treatment continuum for metastatic castration-resistant disease, before the use of chemotherapy.

ZYTIGA also received a positive opinion for an expanded indication from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is under review by other health authorities worldwide.

Excluding skin cancer, prostate cancer is the most frequently diagnosed cancer in men in the U.S. In 2012, the American Cancer Society estimates more than 28,000 men will die from the disease, making it the second leading cause of cancer death behind lung cancer. There are approximately 35,000 new cases of mCRPC each year.




You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment